Duloxetine · Cymbalta

Small molecule

Also known as LY248686

Approvedregulatory verdict

Evidence outlook

Approved: Major Depressive Disorder, Diabetic Peripheral Neuropathic Pain, Generalized Anxiety Disorder, Fibromyalgia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • CYMBALTA (duloxetine): chronic musculoskeletal pain
Product first approved 2004dailymed.nlm.nih.gov
EU
  • Treatment of major depressive disorder. Treatment of diabetic peripheral neuropathic pain. Treatment of generalised anxiety disorder. Cymbalta is indicated in adults.
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (92)
Diabetic Peripheral Neuropathic Pain
NCT01089556 · Eli Lilly and Company
2010-03 – 2011-11 · Diabetic Neuropathy, Painful
What this study did
NCT00641719 · Eli Lilly and Company
2008-03 – 2010-03 · Diabetic Neuropathies
What this study did
NCT00552175 · Eli Lilly and Company
2007-11 – 2009-03 · Diabetic Neuropathies
What this study did
Fibromyalgia
NCT01237587 · Eli Lilly and Company
2011-03 – 2017-11-28 · Fibromyalgia
What this study did
NCT01621191 · Eli Lilly and Company
2012-06 – 2014-02 · Fibromyalgia
What this study did
NCT01552057 · Eli Lilly and Company
2012-03 – 2013-12 · Fibromyalgia
What this study did
NCT00552682 · Germans Trias i Pujol Hospital
2007-01 – 2009-07 · Fibromyalgia, HIV-1 Infection
What this study did
NCT00125892 · Eli Lilly and Company
2005-07 – 2007-03 · Fibromyalgia
What this study did
Generalized Anxiety Disorder
NCT01226511 · Eli Lilly and Company
2011-06 – 2013-06 · Anxiety Neuroses, Anxiety States, Neurotic, Neuroses, Anxiety
What this study did
NCT00803361 · Eli Lilly and Company
2008-12 – 2010-01 · Generalized Anxiety Disorder
What this study did
NCT00122850 · Eli Lilly and Company
2004-10 – 2005-11 · Anxiety Disorders
What this study did
Major Depressive Disorder
NCT03068247 · University of Utah
2021-11 – 2023-05 · Major Depressive Disorder
What this study did
NCT02417064 · Janssen Research & Development, LLC
2015-08-10 – 2018-02-20 · Treatment-resistant Depression
What this study did
NCT02493868 · Janssen Research & Development, LLC
2015-10-01 – 2018-02-16 · Depressive Disorder, Treatment-Resistant
What this study did
NCT02418585 · Janssen Research & Development, LLC
2015-08-07 – 2017-11-06 · Treatment-resistant Depression
What this study did
NCT02497287 · Janssen Research & Development, LLC
2015-09-30 – 2017-10-28 · Treatment-resistant Depression
What this study did
NCT02422186 · Janssen Research & Development, LLC
2015-08-20 – 2017-08-10 · Depressive Disorder, Treatment-Resistant
What this study did
NCT01360866 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2011-10 – 2017-05-18 · Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
What this study did
NCT00849901 · Eli Lilly and Company
2009-03 – 2011-10 · Major Depressive Disorder
What this study did
NCT00849693 · Eli Lilly and Company
2009-03 – 2011-09 · Major Depressive Disorder
What this study did
NCT00105989 · Eli Lilly and Company
2005-03 – 2008-01 · Depressive Disorder, Major
What this study did
NCT00384033 · Pfizer
2006-09 – 2007-09 · Depressive Disorder, Major
What this study did
NCT00321490 · AstraZeneca
2006-04 – 2007-05 · Major Depressive Disorder
What this study did
NCT00351910 · AstraZeneca
2006-05 – 2007-04 · Major Depressive Disorder
What this study did
NCT00366652 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-09 – 2006-09 · Depression, Depressive Disorder, Depressive Disorder, Major
What this study did
NCT00191594 · Eli Lilly and Company
2005-03 – 2006-08 · Major Depressive Disorder
What this study did
NCT00191919 · Eli Lilly and Company
2005-05 – 2006-05 · Depressive Disorder, Major
What this study did
NCT02232555 · Boehringer Ingelheim
2005-05 – 2006-05 · Depressive Disorder, Major
What this study did
NCT00191685 · Eli Lilly and Company
2004-05 – 2005-09 · Depressive Disorder, Major
What this study did
NCT00489775 · Eli Lilly and Company
2004-01 – 2005-06 · Major Depressive Disorder
What this study did
NCT00062673 · Eli Lilly and Company
2003-03 – 2004-07 · Depression, Cognition
What this study did
NCT00042562 · Eli Lilly and Company
2002-12 – 2003-12 · Major Depressive Disorder
What this study did
NCT00042575 · Eli Lilly and Company
2002-06 – 2002-08 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT06407401 · European Organisation for Research and Treatment of Cancer - EORTC
2024-12 – 2028-11-30 · ER+ Breast Cancer, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Drug-Related Side Effects and Adverse Reactions, Musculoskeletal Pain
What this study did
NCT06860984 · Tanta University
2025-03-10 – 2027-07-10 · Biliary Disease
What this study did
NCT06606067 · Parc de Salut Mar
2024-09-03 – 2026-12-31 · Chronic Post-surgical Pain
What this study did
Phase 2/3 (7)
Major Depressive Disorder
NCT00215228 · Duke University
2005-07 – 2007-08 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT04137107 · Alliance for Clinical Trials in Oncology
2020-06-17 – 2026-12-31 · Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
What this study did
NCT03037073 · Assiut University
2017-04-15 – 2019-11-30 · Postoperative Myalgia
What this study did
NCT00375973 · University of Cincinnati
2006-09 – 2014-03 · Fatigue Syndrome, Chronic
What this study did
NCT00457730 · Brown, Theodore R., M.D., MPH
2007-01 – 2012-08 · Multiple Sclerosis
What this study did
NCT00370656 · University of Surrey
2007-02 – 2009-05 · Diabetes Mellitus, Peripheral Neuropathies
What this study did
NCT00136383 · Duke University
2005-03 – 2007-06 · Depressive Symptoms
What this study did
Phase 2 (34)
Diabetic Peripheral Neuropathic Pain
NCT06614322 · University of Rochester
2026-02-02 – 2028-06-01 · Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
What this study did
NCT00837941 · Merck Sharp & Dohme LLC
2009-04 – 2009-09 · Painful Diabetic Neuropathy
What this study did
Major Depressive Disorder
NCT00529789 · Eli Lilly and Company
2007-08 – 2008-09 · Major Depressive Disorder
What this study did
NCT00331799 · Duke University
2007-04 – 2008-07 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT07649291 · VA Office of Research and Development
2027-03-01 – 2032-09-01 · Knee Osteoarthritis, Pain, Depression
What this study did
NCT04970121 · Yan Yang, MD, Ph.D
2021-08-21 – 2027-12-01 · Chemotherapy-induced Peripheral Neuropathy, Pain, Solid Tumor
What this study did
NCT07431606 · University of Pennsylvania
2026-05-01 – 2027-10-31 · Inflammatory Bowel Diseases
What this study did
NCT06914557 · Fox Chase Cancer Center
2025-03-03 – 2027-06-30 · CIPN - Chemotherapy-Induced Peripheral Neuropathy, Pain
What this study did
NCT04560673 · M.D. Anderson Cancer Center
2020-07-10 – 2026-12-31 · Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
What this study did
NCT05110144 · Mayo Clinic
2021-11-01 – 2026-12 · Refractory Chronic Cough
What this study did
NCT05120934 · Mayo Clinic
2021-11-01 – 2026-10 · Interstitial Lung Disease
What this study did
NCT06551051 · Fudan University
2024-08-06 – 2025-12-30 · Solid Tumour
What this study did
NCT04111627 · University of Maryland, Baltimore
2021-10-07 – 2025-08-11 · Knee Osteoarthritis, Depression
What this study did
NCT05611749 · Scripps Health
2023-05-30 – 2024-03-25 · Acute Post-operative Pain, Chronic Post Operative Pain, Narcotic Use, Opioid Use, Opioid Addiction
What this study did
NCT05486026 · Hawler Medical University
2022-08-20 – 2023-01-02 · Osteo Arthritis Knee
What this study did
NCT05115123 · Mansoura University
2022-03-02 – 2022-04-30 · Pain, Postoperative
What this study did
NCT04224584 · Kristian Kjær Petersen
2020-01-01 – 2021-07-01 · Osteoarthritis, Knee
What this study did
NCT04294953 · Assiut University
2020-03-01 – 2021-04-01 · Colorectal Cancer
What this study did
NCT04727502 · National Cancer Institute, Egypt
2020-12-20 – 2021-04 · Drug Effect
What this study did
NCT01846182 · VA Office of Research and Development
2015-06-24 – 2019-08-01 · Gulf War Illness
What this study did
NCT01912612 · University of Michigan Rogel Cancer Center
2013-10-30 – 2019-06-28 · Pain
What this study did
NCT03315533 · Rhode Island Hospital
2018-01-19 – 2019-04-01 · Musculoskeletal Pain
What this study did
NCT03038867 · Weill Medical College of Cornell University
2016-12-12 – 2018-08-31 · Infertility, Male, Depression
What this study did
NCT03364075 · Mark Ware
2017-09-01 – 2018-05-31 · Low Back Pain
What this study did
NCT02857244 · University of Chicago
2016-11 – 2017-11 · Parkinson's Disease
What this study did
NCT02307305 · Hanyang University Seoul Hospital
2014-08 – 2016-12 · Neuropathic Pain
What this study did
NCT00929344 · The Scripps Research Institute
2009-07 – 2014-10 · Alcohol Dependence
What this study did
NCT01223001 · Rehabilitation Hospital of Indiana
1996-09 – 2011-07 · Traumatic Brain Injury, Depression
What this study did
NCT00863057 · National Institute of Allergy and Infectious Diseases (NIAID)
2009-05 – 2010-12 · HIV Infections, Peripheral Neuropathy
What this study did
NCT00940693 · Université de Montréal
2009-08 – 2010-12 · Attention Deficit Disorder With Hyperactivity
What this study did
NCT00190567 · Eli Lilly and Company
2001-10 – 2006-04 · Urinary Stress Incontinence
What this study did
NCT00190606 · Eli Lilly and Company
2002-01 – 2006-04 · Urinary Stress Incontinence
What this study did
NCT00475696 · Eli Lilly and Company
2002-11 – 2005-03 · Urinary Incontinence
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT05814640 · First Affiliated Hospital of Chongqing Medical University
2023-02-20 – 2027-07-01 · Depression, Sequestra
What this study did
NCT05949229 · Amira Hassan Ahmed Ali
2023-08 – 2026-12 · Post Operative Delirium
What this study did
NCT03110172 · Dalian Municipal Central Hospital
2017-01 – 2017-07 · Osteoarthritis Of Knee
What this study did
Phase 1 (22)
Diabetic Peripheral Neuropathic Pain
NCT05292066 · Aga Khan University
2022-10 – 2022-12 · Diabetic Peripheral Neuropathic Pain
What this study did
Major Depressive Disorder
NCT03623711 · Yuqi Cheng
2018-08-01 – 2022-12-31 · Major Depressive Disorder, Depression, Unipolar
What this study did
NCT02869035 · Copenhagen University Hospital, Rigshospitalet
2016-08 – 2019-07 · Major Depressive Disorder
What this study did
NCT00414323 · Eli Lilly and Company
2006-11 – 2007-05 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT07400471 · Chattogram International Dental College
2026-02-06 – 2027-04-30 · Post Endodontic Pain, Mechanical Detection Threshold, Mechanical Pain Threshold, Mechanical Pain Sensitivity
What this study did
NCT04862845 · Cairo University
2021-07-30 – 2026-01-01 · Postoperative Pain
What this study did
NCT05065671 · Rutgers, The State University of New Jersey
2022-02-01 – 2025-09-23 · Microbial Colonization
What this study did
NCT03575403 · Craig Rush
2018-09-01 – 2023-03-15 · Alcohol Use Disorder
What this study did
NCT04178993 · Craig Rush
2019-09-01 – 2021-05-05 · Methamphetamine Use Disorder
What this study did
NCT04723238 · Laboratorios Andromaco S.A.
2021-01-23 – 2021-03-26 · Bioequivalence
What this study did
NCT04751318 · Laboratorios Andromaco S.A.
2021-02-27 – 2021-03-16 · Bioequivalence
What this study did
NCT02700711 · University of Kentucky
2016-02 – 2018-06 · Cocaine Use Disorder
What this study did
NCT01688570 · Medical College of Wisconsin
2011-08 – 2015-05 · Stroke
What this study did
NCT02174822 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2014-01 – 2014-04 · Drug-drug Interaction
What this study did
NCT00990067 · University Hospital, Basel, Switzerland
2009-11 – 2010-05 · Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders
What this study did
NCT00933452 · Shanghai Mental Health Center
2009-07 – 2009-12 · Healthy
What this study did
NCT00763178 · Yale University
2007-02 – 2009-12 · Posttraumatic Stress Disorder
What this study did
NCT02291367 · Dr. Reddy's Laboratories Limited
2008-05 – 2008-05 · Healthy
What this study did
NCT02291341 · Dr. Reddy's Laboratories Limited
2008-05 – 2008-05 · Healthy
What this study did
NCT00533026 · Eli Lilly and Company
2007-07 – 2007-10 · Anticoagulant Effect of Warfarin When Taken With Duloxetine.
What this study did
NCT00387413 · GlaxoSmithKline
2006-10-02 – 2007-05-31 · Hyperalgesia
What this study did
NCT02232542 · Boehringer Ingelheim
2003-06 – 2003-08 · Healthy
What this study did
Phase 4 (107)
Diabetic Peripheral Neuropathic Pain
NCT05296759 · Alexandria University
2021-02-01 – 2022-03-08 · Diabetic Neuropathies
What this study did
NCT04246619 · KRKA
2019-11-12 – 2021-12-21 · Painful Diabetic Peripheral Neuropathy
What this study did
NCT02417935 · Eli Lilly and Company
2015-04 – 2017-05-13 · Diabetic Peripheral Neuropathic Pain
What this study did
NCT00619983 · Wake Forest University
2008-02 – 2013-05 · Diabetic Neuropathic Pain, Chronic Low Back Pain
What this study did
NCT01116531 · Turku University Hospital
2010-04 – 2012-12 · Diabetic Polyneuropathy, Postherpetic Neuralgia
What this study did
NCT00844194 · Boehringer Ingelheim
2009-02 – 2010-06 · Diabetic Neuropathies, Depressive Disorder, Major
What this study did
NCT00385671 · Eli Lilly and Company
2006-09 – 2009-11 · Diabetic Neuropathy, Painful
What this study did
NCT00322621 · Eli Lilly and Company
2006-04 – 2007-10 · Diabetic Neuropathies
What this study did
NCT00266643 · Eli Lilly and Company
2005-12 – 2007-04 · Diabetic Neuropathy, Painful
What this study did
Fibromyalgia
NCT01619566 · University of California, San Diego
2012-06 – 2015-01 · Fibromyalgia
What this study did
NCT01077375 · Forest Laboratories
2010-02 – 2011-01 · Fibromyalgia
What this study did
NCT00965081 · Eli Lilly and Company
2009-09 – 2010-11 · Fibromyalgia, Primary, Fibromyalgia, Secondary
What this study did
NCT01089621 · Eli Lilly and Company
2010-03 – 2010-08 · Fibromyalgia
What this study did
NCT00673452 · Eli Lilly and Company
2008-06 – 2009-07 · Fibromyalgia
What this study did
Generalized Anxiety Disorder
NCT01118780 · Eli Lilly and Company
2010-10 – 2012-07 · Generalized Anxiety Disorder
What this study did
NCT00961298 · West Penn Allegheny Health System
2009-09 – 2011-12 · Irritable Bowel Syndrome, Generalized Anxiety Disorder
What this study did
Major Depressive Disorder
NCT04388189 · Alto Neuroscience
2020-10-15 – 2023-05-30 · Major Depressive Disorder
What this study did
NCT04697693 · New York State Psychiatric Institute
2021-03-03 – 2021-05-20 · Post Traumatic Stress Disorder, Major Depressive Disorder
What this study did
NCT02711215 · Medical University of Vienna
2015-05 – 2020-01 · Major Depressive Disorder
What this study did
NCT01764867 · Shanghai Mental Health Center
2012-06 – 2014-12 · Major Depressive Disorder
What this study did
NCT01754493 · New York State Psychiatric Institute
2008-12 – 2014-12 · Major Depression, Irritable Bowel Syndrome
What this study did
NCT01391221 · Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
2011-07 – 2013-08 · Major Depression
What this study did
NCT01051466 · Eli Lilly and Company
2010-01 – 2013-03 · Major Depressive Disorder, Healthy Participants
What this study did
NCT00889369 · Hamilton Health Sciences Corporation
2009-05 – 2012-06 · Major Depressive Disorder
What this study did
NCT00960986 · Eli Lilly and Company
2009-08 – 2011-04 · Major Depressive Disorder (MDD)
What this study did
NCT01070329 · Eli Lilly and Company
2010-03 – 2011-03 · Major Depressive Disorder
What this study did
NCT00985504 · Eli Lilly and Company
2009-09 – 2010-12 · Major Depressive Disorder
What this study did
NCT01000805 · Eli Lilly and Company
2009-11 – 2010-10 · Major Depressive Disorder
What this study did
NCT00696293 · University of Pittsburgh
2007-05 – 2010-04 · Major Depressive Disorder, Back Pain, Aged
What this study did
NCT00810069 · Eli Lilly and Company
2008-11 – 2010-03 · Major Depressive Disorder
What this study did
NCT00406848 · Eli Lilly and Company
2006-11 – 2009-11 · Major Depressive Disorder
What this study did
NCT00696774 · Eli Lilly and Company
2008-06 – 2009-07 · Depressive Disorder, Major
What this study did
NCT00437125 · Eli Lilly and Company
2007-03 – 2009-07 · Major Depressive Disorder, Idiopathic Parkinson Disease
What this study did
NCT01035073 · University of Pennsylvania
2006-04 – 2009-05 · Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
What this study did
NCT00532480 · Indiana University
2007-09 – 2009-04 · Major Depression
What this study did
NCT00536471 · Eli Lilly and Company
2007-09 – 2008-12 · Major Depressive Disorder
What this study did
NCT02229825 · Boehringer Ingelheim
2007-02-09 – 2008-08-26 · Depressive Disorder, Major
What this study did
NCT00422162 · Eli Lilly and Company
2007-02 – 2008-08 · Major Depressive Disorder
What this study did
NCT00517985 · University of Arizona
2007-02 – 2008-06 · Major Depressive Disorder
What this study did
NCT00531895 · Kraepelin Psiquiatria Clinica
2006-04 – 2007-03 · Major Depression, Chronic Primary Headache
What this study did
NCT00191932 · Eli Lilly and Company
2004-08 – 2006-03 · Major Depressive Disorder
What this study did
NCT00191061 · Eli Lilly and Company
2004-10 – 2006-01 · Depressive Disorder
What this study did
NCT00479726 · Eli Lilly and Company
2004-08 – 2005-01 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT06232473 · Aarhus University Hospital
2024-01-01 – 2029-11-01 · Functional Disorder
What this study did
NCT07759336 · Benedict Alter
2026-09-15 – 2029-03 · Knee Osteoarthritis (Knee OA), Chronic Pain, Chronic Knee Pain
What this study did
NCT05851898 · Wake Forest University Health Sciences
2024-04-08 – 2028-12 · Depression in Old Age, Fragility Fracture
What this study did
NCT06245109 · Northwestern University
2024-02-26 – 2028-03-15 · Knee Osteoarthritis
What this study did
NCT06423716 · Sunnybrook Health Sciences Centre
2024-11-01 – 2027-12-31 · Knee Osteoarthritis
What this study did
NCT05851976 · Montefiore Medical Center
2023-10-04 – 2027-05 · Back Pain, Low
What this study did
NCT05976347 · Wake Forest University Health Sciences
2025-06-25 – 2027-05 · Depression
What this study did
Early phase / not applicable (54)
Diabetic Peripheral Neuropathic Pain
NCT07785544 · Bangladesh Medical University
2026-09-20 – 2027-08 · Painful Diabetic Peripheral Neuropathy
What this study did
Fibromyalgia
NCT07326163 · Bilecik Seyh Edebali Universitesi
2026-03-01 – 2027-01-01 · Fibromyalgia, Aromatherapy, Cost
What this study did
NCT04316702 · Assaf-Harofeh Medical Center
2020-03-01 – 2023-11-30 · Fibromyalgia, Emotional Trauma
What this study did
NCT03325959 · Assaf-Harofeh Medical Center
2017-03-01 – 2022-06-01 · Fibromyalgia, Hyperbaric Oxygen
What this study did
NCT05937711 · Ilker Fatih Sari
2020-11-02 – 2022-05-23 · Fibromyalgia
What this study did
NCT01127490 · Albany Medical College
2010-05-05 – 2015-09-09 · Fibromyalgia
What this study did
NCT01268631 · Tel-Aviv Sourasky Medical Center
2011-01 – 2013-01 · Fibromyalgia
What this study did
Generalized Anxiety Disorder
NCT00491348 · National Taiwan University Hospital
2007-04 – 2008-11 · Worry, Anxiety
What this study did
Major Depressive Disorder
NCT04847245 · Peking University
2021-05-01 – 2023-03-01 · Chronic Visceral Pain, Major Depressive Disorder
What this study did
NCT03121573 · Taichung Veterans General Hospital
2014-12-15 – 2017-01-17 · Major Depressive Disorder
What this study did
NCT01896349 · Hospital de Clinicas de Porto Alegre
2013-04 – 2014-11 · Treatment Resistant Depression
What this study did
NCT01650740 · Sunnybrook Health Sciences Centre
2012-08 – 2014-11 · Major Depressive Disorder
What this study did
NCT00617045 · Yale University
2007-07 – 2013-05 · Postpartum Depression, Major Depressive Disorder
What this study did
NCT00933439 · University of Texas Southwestern Medical Center
2005-02 – 2007-09 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT07731750 · University of Michigan
2026-07-23 – 2030-07 · Chronic Low-back Pain
What this study did
NCT07421427 · Cairo University
2026-02-21 – 2027-01-01 · Amantadine, Duloxetine, Pregabalin, Mastectomy, Pain Syndrome
What this study did
NCT05311774 · Assiut University
2022-04-01 – 2025-10-01 · Cancer Pain
What this study did
NCT06087211 · National Cancer Institute, Egypt
2023-10-10 – 2025-01-01 · Duloxetine, Magnesium Sulphate, Post-mastectomy Pain Syndrome
What this study did
NCT06429605 · Erzincan Military Hospital
2024-05-20 – 2024-12-27 · Vaginal Hysterectomy, Postoperative Pain, vNOTES
What this study did
NCT05256342 · Rambam Health Care Campus
2021-12-30 – 2024-04-08 · Knee, Osteoarthritis (OA), Biomarkers for Prediction of OA Treatment Efficacy
What this study did
NCT04313335 · Beijing Tiantan Hospital
2021-03-01 – 2023-05-16 · Postherpetic Neuralgia
What this study did
NCT05442268 · Tanta University
2022-07-16 – 2023-01-31 · Modified Radical Mastectomy, Postoperative Analgesia
What this study did
NCT04719585 · The Catholic University of Korea
2021-01 – 2022-12 · Total Knee Arthroplasty, Osteoarthritis, Knee
What this study did
NCT04732455 · Gamal Mohamed Taha Abouelmagd
2021-01-15 – 2022-07-05 · Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Breast Cancer
What this study did
NCT03148522 · Peking University
2017-06-01 – 2022-06-30 · Diagnosis and Treatment of Depression
What this study did
NCT03276689 · Rambam Health Care Campus
2017-10-19 – 2020-12-30 · Neuropathic Pain
What this study did
NCT03880916 · The Catholic University of Korea
2019-03-30 – 2020-03-31 · Osteoarthritis, Knee
What this study did
NCT03560427 · Assiut University
2018-09-10 – 2020-03-14 · Acute Pain
What this study did
NCT04140253 · Comenius University
2019-02-01 – 2020-03-10 · Stress Urinary Incontinence in Women
What this study did
NCT03468348 · Assiut University
2018-04-01 – 2020-02-10 · Acute Pain
What this study did
NCT03549026 · Assiut University
2018-01-05 – 2019-12-25 · Acute Pain
What this study did
NCT02655354 · University of Washington
2015-10 – 2019-11 · Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation, Substance-Related Disorders, Mild Cognitive Impairment, Quality of Life, Pain, Wounds and Injury, Brain Injuries, Chronic Disease
What this study did
NCT03054220 · Jules Desmeules
2016-07 – 2018-12 · Healthy
What this study did
NCT03350334 · Acibadem University
2017-12-04 – 2018-03-15 · Laparoscopic Hysterectomy, Postoperative Recovery, Postoperative Pain
What this study did
NCT01470352 · d_yarnitsky
2011-11-16 – 2017-11-06 · Migraine
What this study did
NCT02672202 · Rambam Health Care Campus
2016-02 – 2017-05 · Post-operative Chronic Pain
What this study did
NCT02600247 · The Catholic University of Korea
2015-11 – 2016-11 · Osteoarthritis
What this study did
NCT00360399 · Emory University
2006-08 – 2015-04 · Depression
What this study did
NCT02020122 · Rambam Health Care Campus
2014-01 – 2015-01 · Pain
What this study did
NCT01470339 · Rambam Health Care Campus
2011-12 – 2014-07 · Pain
What this study did
NCT01359514 · Rambam Health Care Campus
2008-04 – 2014-01 · Pain
What this study did
NCT01363284 · Rambam Health Care Campus
2010-06 – 2012-08 · Diabetes, Painful Neuropathy
What this study did
NCT01269866 · Dr. Jesus Gutierrez Stone
2010-12 – 2012-05 · Systemic Lupus Erythematosus
What this study did
NCT00660751 · Rambam Health Care Campus
2007-08 – 2012-04 · Healthy
What this study did
NCT01404871 · Sunnybrook Health Sciences Centre
2009-04 – 2011-12 · Obsessive Compulsive Disorder
What this study did
NCT02903238 · Northwestern University
2011-07 – 2011-12 · Pain, Osteoarthritis
What this study did
NCT00981149 · University of Maryland, Baltimore
2009-05 – 2011-12 · Temporomandibular Joint Disorders
What this study did
NCT01028352 · University of Michigan Rogel Cancer Center
2008-10 – 2011-10 · Breast Cancer
What this study did
NCT01425827 · University of Alexandria
2010-11 – 2011-07 · Pain Reduction, Function Improvement
What this study did
NCT00388414 · Stanford University
2006-09 – 2010-01 · Low Back Pain
What this study did
Used as active comparator (35)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Diabetic Peripheral Neuropathic Pain
NCT06715462 · Eurofarma Laboratorios S.A.
2026-04 – 2028-03 · Painful Diabetic Peripheral Neuropathy (PDPN)
What this study did
Generalized Anxiety Disorder
NCT00730691 · Takeda
2008-06 – 2009-02 · Generalized Anxiety Disorder
What this study did
Major Depressive Disorder
NCT07253207 · Zhejiang Huahai Pharmaceutical Co., Ltd.
2024-10-17 – 2025-07-22 · Major Depressive Disorder (MDD)
What this study did
NCT04364997 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2020-06-18 – 2021-09-22 · Major Depressive Disorder
What this study did
NCT01153009 · Takeda
2010-06 – 2012-03 · Depressive Disorder, Major
What this study did
NCT00672620 · Takeda
2008-04 – 2008-12 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT05840562 · Institut Cancerologie de l'Ouest
2023-10-20 – 2028-03 · Chemotherapy-induced Peripheral Neuropathy
What this study did
NCT06025474 · Federico II University
2023-01-01 – 2024-07-24 · Burning Mouth Syndrome
What this study did
Phase 2/3 (2)
Fibromyalgia
NCT03487211 · Shaheed Zulfiqar Ali Bhutto Medical University
2018-04-09 – 2020-02-26 · Fibromyalgia
What this study did
Other / comorbidity
NCT05786599 · University of British Columbia
2025-03-21 – 2026-03 · Chemotherapy-induced Peripheral Neuropathy
What this study did
Phase 2 (13)
Diabetic Peripheral Neuropathic Pain
NCT07882238 · Assiut University
2026-11 – 2027-12 · Diabetic Peripheral Neuropathy, Painful Diabetic Neuropathy, Diabetic Foot Pain, Neuralgia
What this study did
NCT01579279 · AbbVie (prior sponsor, Abbott)
2012-04 – 2012-05 · Diabetic Neuropathic Pain
What this study did
NCT00507936 · AbbVie (prior sponsor, Abbott)
2007-08 – 2008-10 · Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Neuralgia, Diabetic
What this study did
NCT00603265 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2007-11 – 2008-08 · Peripheral Neuropathy, Neuropathic Pain
What this study did
Major Depressive Disorder
NCT06842992 · Jiangsu Nhwa Pharmaceutical Co., Ltd.
2024-12-04 – 2025-09-12 · Major Depressive Disorder (MDD)
What this study did
NCT05018013 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2021-08-21 – 2022-12-30 · Major Depressive Disorder (MDD)
What this study did
NCT01564862 · Takeda
2012-04 – 2014-02 · Depressive Disorder, Major
What this study did
NCT01369095 · Bristol-Myers Squibb
2011-07 – 2013-05 · Depression
What this study did
NCT01309945 · Bristol-Myers Squibb
2011-04 – 2013-01 · Depression
What this study did
NCT01288079 · AstraZeneca
2011-02 – 2012-08 · Major Depressive Disorder
What this study did
NCT01145755 · AstraZeneca
2010-05 – 2010-11 · Major Depressive Disorder
What this study did
NCT00599911 · H. Lundbeck A/S
2007-10 – 2009-04 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT03812523 · Southeastern Regional Medical Center
2019-06 – 2021-10 · Chemotherapy-Induced Peripheral Neuropathy
What this study did
Phase 1 (1)
Fibromyalgia
NCT05508516 · China-Japan Friendship Hospital
2022-09-01 – 2024-10-18 · Fibromyalgia
What this study did
Phase 4 (6)
Diabetic Peripheral Neuropathic Pain
NCT07800468 · Wah Medical college , POF hospital
2026-12-01 – 2027-04-01 · Painful Diabetic Neuropathy (PDN), Diabetic Neuropathies, Type 2 Diabetes
What this study did
Major Depressive Disorder
NCT01148472 · H. Lundbeck A/S
2005-09 – 2006-11 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT03249311 · University of Ottawa
2018-03-02 – 2022-05-01 · None (i.e. Healthy Volunteers)
What this study did
NCT03729284 · Pfizer
2020-03-30 – 2020-06-07 · Healthy
What this study did
NCT03794154 · Pfizer
2020-03-30 – 2020-06-05 · Healthy
What this study did
NCT02535000 · Serviço de Anestesiologia de Joinville
2014-01-01 – 2015-10-30 · Intervertebral Disc Degeneration
What this study did
Early phase / not applicable (5)
Fibromyalgia
NCT07203339 · Hospital de Clinicas de Porto Alegre
2025-09-30 – 2028-12 · Fibromyalgia (FM), tDCS, Duloxetine, BDNF, EEG
What this study did
Other / comorbidity
NCT07645482 · Beni-Suef University
2026-07-12 – 2026-08-02 · Peripheral Neuropathy With Type 2 Diabetes
What this study did
NCT06711978 · Pusan National University Yangsan Hospital
2024-12-01 – 2026-04-15 · CIPN, CIPN - Chemotherapy-Induced Peripheral Neuropathy, CIPN in Adjuvant Breast Cancer Patients, Duloxetine, Mirogabalin
What this study did
NCT06301061 · Federico II University
2024-04-01 – 2026-04-01 · Pain, Chronic, Lumbosacral Radiculopathy, Radicular; Neuropathic
What this study did
NCT05560516 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2022-12-01 – 2025-12-31 · Qutenza, Duloxetine, Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
What this study did
Appears in other studies (10)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Major Depressive Disorder
NCT04476030 · Biogen
2020-11-09 – 2021-12-22 · Depressive Disorder, Major
What this study did
NCT03434041 · Janssen Research & Development, LLC
2018-05-25 – 2021-04-13 · Depressive Disorder, Treatment-Resistant
What this study did
Phase 1 (1)
Major Depressive Disorder
NCT06965569 · Alar Pharmaceuticals Inc.
2025-04-21 – 2025-12-30 · Treatment Resistant Depression
What this study did
Phase 4 (1)
Other / comorbidity
NCT00177671 · University of Pittsburgh
2003-12 – 2009-09 · Depression, Dementia
What this study did
Early phase / not applicable (5)
Major Depressive Disorder
NCT00149110 · Hillerod Hospital, Denmark
2005-09 – 2009-03 · Major Depression
What this study did
Other / comorbidity
NCT07593313 · Nanchong Central Hospital
2024-01-01 – 2029-08-01 · Central Post-Stroke Pain
What this study did
NCT07025590 · Guangdong Provincial People's Hospital
2025-04-22 – 2027-03-31 · Cardiovascular Diseases (CVD), Depression Anxiety Disorder
What this study did
NCT06896994 · Beijing Tiantan Hospital
2025-04-01 – 2026-05-01 · Postherpetic Neuralgia
What this study did
NCT05254652 · The Catholic University of Korea
2022-05 – 2023-05 · Osteoarthritis
What this study did

Competitive landscape

Other Serotonin/norepinephrine transporter drugs

Ammoxetine. Compare all 2 Serotonin/norepinephrine transporter drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Major Depressive Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Duloxetine (Cymbalta): this drugApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT01360645: Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14): Brexpiprazole 2 mg/Day + ADT -8.27 Units on a scale (Standard Error 0.61) vs Double-blind Placebo + ADT -5.15 Units on a scale (Standard Error 0.6)
NCT01360632: Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set (Baseline and Week 14): Brexpiprazole (1mg) + ADT -7.65 Units on a scale (Standard Error 0.5) | Brexpiprazole (3mg) + ADT -7.98 Units on a scale (Standard Error 0.51) vs Placebo + ADT -6.45 Units on a scale (Standard Error 0.51)
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Partial signal
NCT03738215: Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) (Baseline and Week 6): Cariprazine 1.5 mg/Day + ADT -14.1 score on a scale (Standard Error 0.7) | Cariprazine 3 mg/Day + ADT -13.1 score on a scale (Standard Error 0.7) vs Placebo + ADT -11.5 score on a scale (Standard Error 0.7)
Dextromethorphan / Bupropion (Auvelity)ApprovedSmall moleculesigma-1/NMDA, Dopamine/norepinephrine transporterPartial signal
NCT04019704: Change in MADRS Total Score From Baseline to Week 6 (6 weeks): AXS-05 15.91 score on a scale (Standard Error 0.921) vs Placebo 12.04 score on a scale (Standard Error 0.862)
NCT02741791: Primary endpoint, MADRS total score change from baseline to Week 6: -11.6 with AXS-05 vs -9.4 with bupropion (active comparator); difference not statistically significant, p=0.117 missed
Esketamine (Spravato)ApprovedSmall moleculeNMDA receptorPartial signal
NCT02418585: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) -21.4 Units on a scale (Standard Deviation 12.32) vs Intranasal Placebo Plus Oral AD -17 Units on a scale (Standard Deviation 13.88)
NCT02417064: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine 56 mg Plus Oral Antidepressant -19 Units on a scale (Standard Deviation 13.86) | Intranasal Esketamine 84 mg Plus Oral AD -18.8 Units on a scale (Standard Deviation 14.12) vs Oral AD Plus Intranasal Placebo -14.8 Units on a scale (Standard Deviation 15.07) missed
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorWeak signal
NCT05061706: Montgomery-Asberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 units on a scale (Standard Error 0.56) | Placebo -10.2 units on a scale (Standard Error 0.54)
NCT04985942: Montgomery-Åsberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 score on a scale (Standard Error 0.54) | Placebo -9.8 score on a scale (Standard Error 0.53)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Vortioxetine (Trintellix)ApprovedSmall moleculeSerotonin transporter + multiple 5-HT receptorsPartial signal
NCT00596817: Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator (Within first 24 weeks of the double-blind period): Vortioxetine: 5 or 10 mg 13.2 percentage of patients who relapsed vs Placebo 26 percentage of patients who relapsed
NCT02709655: Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B (Baseline (Week 4 of Phase A), Week 8 of Phase B): Double-Blind: Vortioxetine 10 mg -19.2 units on a scale (Standard Error 1.37) | Double-Blind: Vortioxetine 20 mg -19.94 units on a scale (Standard Error 1.37) vs Double-Blind: Placebo -17.48 units on a scale (Standard Error 1.35) | Double-Blind: Fluoxetine 20 mg -20.78 units on a scale (Standard Error 1.6) missed
AmmoxetinePhase 3Small moleculeSerotonin/norepinephrine transporterPartial signal
NCT06827431: Primary endpoint, week-8 MADRS change: significantly better than placebo (P<0.0001) and numerically better than sertraline (2026-07-27).
Ansofaxine HydrochloridePhase 3Small moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT04853407: MADRS total score change from baseline at Week 8: ansofaxine 80 mg -20.0, ansofaxine 160 mg -19.9, placebo -14.6 (p<0.0001).
AzetukalnerPhase 3Small moleculeKv7 potassium channelnot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
DeupsilocinPhase 3Small molecule5-HT2A receptorPartial signal
NCT05385783: Primary endpoint (3-week MADRS change vs placebo): -14.08 point difference after a single 12mg dose (p=0.0005, Cohen's d=2.151)
KH607Phase 3Small moleculeGABA-A receptorPartial signalNo reviewed efficacy summary in this indication
Lysergide Tartrate (LSD) (DT120)Phase 3Small molecule5-HT2A receptorReliable signal
NCT06941844: Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001.
Milsaperidone (VHX-896)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
OsavampatorPhase 3Small moleculeAMPA receptor (positive allosteric modulator)Partial signal
NCT05203341: MADRS total score change at Day 28 vs placebo (company topline): one dose -4.3 (p = 0.0159); the other dose -3.0 (p = 0.0873, not significant). Day 56: -7.5 (p = 0.0016) and -3.6 (p = 0.1082).
Psilocybin (COMP360)Phase 3Small molecule5-HT2A receptorReliable signal
NCT05711940: COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001.
NCT05624268: Change in MADRS total score from baseline to Week 6 (COMP005 trial): COMP360 25 mg vs placebo, mean treatment difference -3.6 points (95% CI -5.7 to -1.5; p<0.001)
SeltorexantPhase 3Small moleculeOrexin-2 receptor (OX2R)Partial signal
NCT04533529: Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 (Baseline (Day 1), Day 43): DB Treatment Phase: Seltorexant 20 mg -12.9 Units on a scale (Standard Deviation 9.63) vs Double Blind (DB) Treatment Phase: Placebo -10.5 Units on a scale (Standard Deviation 10.26)
NCT04513912: Response (>=50% MADRS improvement) at week 26: 57.4% seltorexant vs 53.4% quetiapine XR; did not reach statistical significance missed
Solriamfetol (Sunosi)Phase 3Small moleculeDopamine/norepinephrine transporterPartial signal
NCT06360419: In the overall patient population the study did not demonstrate a statistically significant change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo, the study's primary endpoint. Patients with MDD with severe excessive daytime sleepiness (n=51) and without severe EDS (n=295) were randomized to solriamfetol 300 mg or placebo. missed
D-Cycloserine / Lurasidone (NRX-101)Phase 2/3Small moleculeNMDA receptor (glycine site) + dopamine/5-HT receptornot yet gradedNo reviewed efficacy summary in this indication
Mitizodone PhosphatePhase 2/3Small moleculeSerotonin transporter/5-HT receptorWeak signalNo reviewed efficacy summary in this indication
ACP-211Phase 2Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancerPartial signal
NCT05117632: MADRS reduction at Week 6: 15.5 points (biomarker-defined group) vs 10.6 points (biomarker-negative group); clinical response (>=50% MADRS reduction): 61% vs 33%
ALTO-203Phase 2Small moleculeHistamine H3 receptor (antagonist / inverse agonist)Partial signalNo reviewed efficacy summary in this indication
ALTO-300Phase 2Small moleculeMelatonergic (MT) receptors (agonist) + serotonin receptorWeak signalNo reviewed efficacy summary in this indication
Arketamine (PRT042)Phase 2Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
AV-101Phase 2Small moleculeNMDA receptorPartial signal
NCT02484456: Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) missed
BI 1569912Phase 2Small moleculeNMDA receptorPartial signal
NCT06558344: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) missed
NCT06280235: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements from baseline and Day 8, Week 4, Week 6 after first drug administration. MMRM estimates of change from baseline to Week 6 in MADRS total score is reported.): 5 mg BI 1569912 -7.8 units on a scale (95% CI -11 to -4.6) | 10 mg BI 1569912 -11.9 units on a scale (95% CI -15 to -8.7) | 20 mg BI 1569912 -12.3 units on a scale (95% CI -14.6 to -10) vs Placebo -12 units on a scale (95% CI -14.2 to -9.7) missed
BlixeprodilPhase 2Small moleculeNMDA receptorWeak signalFeatured results are safety only in this race
BPL-003 (mebufotenin Benzoate)Phase 2Small molecule5-HT2A receptorPartial signal
NCT05870540: MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025).
BretisilocinPhase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
Cyclobenzaprine (Tonmya)Phase 2Small molecule5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)not yet gradedNo reviewed efficacy summary in this indication
DT-101Phase 2Small moleculeAMPA receptor (positive allosteric modulator)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
Emestedastat (Xanamem)Phase 2Small molecule11-beta-HSD1Partial signal
NCT05657691: Primary endpoint (Attention Composite cognitive score, week 6) missed: least squares mean change 0.32 (emestedastat) vs 0.46 (placebo), difference -0.13 (95% CI -0.32 to 0.06), p=0.17 favouring placebo. (MADRS depression score was only a secondary endpoint, borderline at p=0.05.) missed
Esketamine (CLE-100)Phase 2Small moleculeNMDA receptorPartial signal
NCT06340958: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) missed
NCT04103892: Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Part B - CLE-100 (Oral Esketamine) -10.72 units on a scale (Standard Error 1.13) vs Part B - Placebo -9.46 units on a scale (Standard Error 1.31) missed
EvifacotrepPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ForvisirvatPhase 2Small moleculeSIRT6Partial signal
NCT04479852: Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Baseline to Week 4): SP-624 -12.6 Score on a scale (Standard Error 0.83) vs Placebo -10.8 Score on a scale (Standard Error 0.84) missed
GlyphAllo (allopregnanolone Prodrug) (SPT-300)Phase 2Small moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
GW117Phase 2Small moleculeMelatonin MT1/MT2 receptor + 5-HT2C receptorPartial signal
NCT06796868: Change in HAMD-17 total score from baseline at Week 8 (FAS, n=276): placebo -13.46, GW117 20mg -14.62, 40mg -14.34, 60mg -13.75; numerically greater reductions with GW117 but not statistically significant vs placebo. missed
HS-10353Phase 2Small moleculeGABA-A receptorWeak signal
NCT05195203: Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses
Hypidone (YL-0919)Phase 2Small moleculeSerotonin transporter/5-HT1A receptor/sigma-1 receptorPartial signalNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
JNJ-89495120Phase 2Small moleculeMuscarinic M1 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LiafensinePhase 2Small moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT05113771: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients (Baseline to Day 42): Liafensine 1mg -15.4 Units on a Scale (Standard Error 1.25) | Liafensine 2mg -15.5 Units on a Scale (Standard Error 1.3) vs Placebo -11 Units on a Scale (Standard Error 1.31)
NCT01369095: In the CN162-007 study, the adjusted mean (SE) change in MADRS total score was -7.3 (0.830) and -6.6 (0.842) for BMS-820836 of 1 and 2 mg, respectively, and -6.9 (0.602) for the continuation group (P = 0.910). missed
LV232Phase 2Small moleculeSerotonin transporter + 5-HT3 receptorWeak signalNo reviewed efficacy summary in this indication
Mebufotenin (5-MeO-DMT) (GH001)Phase 2Small molecule5-HT2A receptorPartial signal
NCT05800860: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001)
NelivaptanPhase 2Small moleculeVasopressin V1B receptorPartial signal
NCT00358631: Change from baseline to Day 56 in HAM-D-17 total score (LS mean, SE): nelivaptan 250mg BID -10.7 (0.94) vs placebo -7.68 (0.95); difference from placebo -3.03 (95% CI -5.66 to -0.39; p=0.0244). 100mg BID nelivaptan and escitalopram 10mg QD arms did not separate from placebo.
NH102Phase 2Small moleculeSerotonin/norepinephrine/dopamine transporter + 5-HT2A receptorPartial signalNo reviewed efficacy summary in this indication
PDC-1421Phase 2BotanicalPolygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)Partial signal
NCT02395978: Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. (From Baseline to Week 6): Part II: 2 PDC-1421 Capsule — ITT population: -13.19 score on a scale (Standard Deviation 9.68); PP population: -13.4 score on a scale (Standard Deviation 9.7) | Part II: 1 PDC-1421 Capsule Plus 1 Placebo — ITT population: -9.21 score on a scale (Standard Deviation 8.32); PP population: -10.4 score on a scale (Standard Deviation 5.18) vs Part II: 2 Placebo — ITT population: -9.2 score on a scale (Standard Deviation 7.98); PP population: -8.6 score on a scale (Standard Deviation 7.61)
Pramipexole / Ondansetron (ALTO-207)Phase 2Small moleculeDopamine D3-preferring D3/D2 receptors (agonist) + 5-HT3 receptornot yet gradedNo reviewed efficacy summary in this indication
RopanicantPhase 2Small moleculeAlpha4beta2 nicotinic acetylcholine receptorPartial signal
NCT06836063: MADRS total score change from baseline vs placebo at Week 6: mean difference -3.572 (FAS, p=0.038), -4.067 (PP set, p=0.023) -- primary endpoint met.
NCT03155503: Safe and well tolerated in healthy subjects at single doses up to 60 mg and multiple doses up to 45 mg once daily. Pharmacokinetics were nonlinear with accumulation on multiple dosing: 1.5- to 2.5-fold higher maximum concentration and 1.6- to 4.0-fold higher AUC from 0 to 24 h on day 14 compared with day 1.
SPN-820Phase 2Small moleculemTORC1Partial signal
NCT05066672: Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. (Baseline to Week 4): NV-5138 (800 or 1600 mg) -12.2 units on a scale (Standard Deviation 9.66) | Placebo -11.6 units on a scale (Standard Deviation 10.64) missed
SPN-821Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (activator)not yet gradedNo reviewed efficacy summary in this indication
VLS-01Phase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
ZelquistinelPhase 2Small moleculeNMDA receptorPartial signal
NCT03726658: Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2): AGN-241751 3mg Daily -9.4 score on a scale (Standard Error 1.57) | AGN-241751 10mg Daily -6.7 score on a scale (Standard Error 1.58) | AGN-241751 25mg Daily -9.5 score on a scale (Standard Error 1.57) vs Placebo Daily -9.3 score on a scale (Standard Error 1.61) missed
ELE-101Phase 1/2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
ALA-3000Phase 1Small moleculeNMDA receptorPartial signalFeatured results are safety only in this race
ApimostinelPhase 1Small moleculeNMDAR agonist/modulatorWeak signalFeatured results are safety only in this race
ENX-104Phase 1Small moleculeDopamine D2/D3 receptor (antagonist)Weak signalNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 8 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(23 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cymbalta (Duloxetine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
December 2026 (5)
Phase 2Refractory Chronic CoughRecruiting
Est. primary completion 2026-12 · NCT05110144 · CT.gov ↗
What to watch
Phase 4THARecruiting
Est. primary completion 2026-12-01 · NCT06807866 · CT.gov ↗
What to watch
Early phase / not applicableFibromyalgiaEnrolling by invitation
Est. primary completion 2026-12-30 · NCT07326163 · CT.gov ↗
What to watch
Phase 1/2Depression, SequestraRecruiting
Est. primary completion 2026-12-31 · NCT05814640 · CT.gov ↗
What to watch
Phase 2Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid NeoplasmActive not recruiting
Est. primary completion 2026-12-31 · NCT04560673 · CT.gov ↗
What to watch
2027 (11)
January 2027 (1)
Early phase / not applicableAmantadine, Duloxetine, Pregabalin, Mastectomy, Pain SyndromeRecruiting
Est. primary completion 2027-01-01 · NCT07421427 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Inflammatory Bowel DiseasesRecruiting
Est. primary completion 2027-03-01 · NCT07431606 · CT.gov ↗
What to watch
Phase 1Post Endodontic Pain, Mechanical Detection Threshold, Mechanical Pain Threshold, Mechanical Pain SensitivityRecruiting
Est. primary completion 2027-03-30 · NCT07400471 · CT.gov ↗
What to watch
Phase 2CIPN - Chemotherapy-Induced Peripheral Neuropathy, PainRecruiting
Est. primary completion 2027-03-30 · NCT06914557 · CT.gov ↗
What to watch
May 2027 (2)
Phase 4Back Pain, LowRecruiting
Est. primary completion 2027-05 · NCT05851976 · CT.gov ↗
What to watch
Phase 4DepressionRecruiting
Est. primary completion 2027-05 · NCT05976347 · CT.gov ↗
What to watch
June 2027 (2)
Early phase / not applicableDiabetic Peripheral Neuropathic PainRecruiting
Est. primary completion 2027-06 · NCT07785544 · CT.gov ↗
What to watch
Phase 3Biliary DiseaseRecruiting
Est. primary completion 2027-06-20 · NCT06860984 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Chemotherapy-induced Peripheral Neuropathy, Pain, Solid TumorRecruiting
Est. primary completion 2027-07-01 · NCT04970121 · CT.gov ↗
What to watch
Phase 4Knee OsteoarthritisRecruiting
Est. primary completion 2027-07-01 · NCT06423716 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4Functional DisorderRecruiting
Est. primary completion 2027-11-01 · NCT06232473 · CT.gov ↗
What to watch
2028 (5)
March 2028 (1)
Phase 4Knee OsteoarthritisRecruiting
Est. primary completion 2028-03-15 · NCT06245109 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3ER+ Breast Cancer, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III …Not yet recruiting
Est. primary completion 2028-04-18 · NCT06407401 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Diabetic Peripheral Neuropathic PainRecruiting
Est. primary completion 2028-06-01 · NCT06614322 · CT.gov ↗
What to watch
December 2028 (2)
Phase 4Depression in Old Age, Fragility FractureRecruiting
Est. primary completion 2028-12 · NCT05851898 · CT.gov ↗
What to watch
Phase 4Knee Osteoarthritis (Knee OA), Chronic Pain, Chronic Knee PainRecruiting
Est. primary completion 2028-12 · NCT07759336 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
Early phase / not applicableChronic Low-back PainRecruiting
Est. primary completion 2030-02 · NCT07731750 · CT.gov ↗
What to watch
2031 (1)
September 2031 (1)
Phase 2Knee Osteoarthritis, Pain, DepressionNot yet recruiting
Est. primary completion 2031-09-01 · NCT07649291 · CT.gov ↗
What to watch

See the full readout calendar ↗